We have shown in the 4T1 and SCC7 mouse models that both unsorted tumor cells and ALDHhigh CSCs express ITGB4, and immunological targeting of ITGB4 combined with anti-PD-L1 immunotherapy elicits significant anti-tumor immunity. Here, ITGB4 is linked to neoplasm.